The estimated Net Worth of Jack W Callicutt is at least $799 Thousand dollars as of 17 November 2022. Mr. Callicutt owns over 4,000 units of Galectin Therapeutics Inc stock worth over $20,862 and over the last 11 years he sold GALT stock worth over $0. In addition, he makes $778,123 as Chief Financial Officer and Secretary at Galectin Therapeutics Inc.
Sign up
Mr. Callicutt GALT stock SEC Form 4 insiders trading
Jack has made over 9 trades of the Galectin Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of GALT stock worth $5,280 on 17 November 2022.
The largest trade he's ever made was exercising 226,000 units of Galectin Therapeutics Inc stock on 19 June 2018 worth over $971,800. On average, Jack trades about 17,953 units every 143 days since 2013. As of 17 November 2022 he still owns at least 7,614 units of Galectin Therapeutics Inc stock.
You can see the complete history of Mr. Callicutt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jack Callicutt biography
Jack W. Callicutt CPA serves as Chief Financial Officer, Secretary of the Company. From August 2012 through June 2013, Mr. Callicutt was the Chief Financial Officer of REACH Health, Inc., a telemedicine technology company headquartered in Alpharetta, GA. From April 2010 through August 2012, Mr. Callicutt was the Chief Financial Officer of Vystar Corporation, a publicly traded company that holds proprietary technology to remove antigenic proteins from natural rubber latex. Prior to that Mr. Callicutt was Chief Financial Officer of IVOX, Inc., Tikvah Therapeutics and Corautus Genetics, a publicly traded biotechnology company which was developing gene therapy for treatment of cardiovascular disease. Mr. Callicutt previously spent more than fourteen years in public accounting, most recently as a senior manager at Deloitte, where he specialized in technology companies from 1989 to 2003. Mr. Callicutt is a Certified Public Accountant and graduated with honors from Delta State University with a B.B.A. in accounting and computer information systems.
What is the salary of Jack Callicutt?
As the Chief Financial Officer and Secretary of Galectin Therapeutics Inc, the total compensation of Jack Callicutt at Galectin Therapeutics Inc is $778,123. There are 1 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
How old is Jack Callicutt?
Jack Callicutt is 53, he's been the Chief Financial Officer and Secretary of Galectin Therapeutics Inc since 2018. There are 13 older and 6 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
What's Jack Callicutt's mailing address?
Jack's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.
Insiders trading at Galectin Therapeutics Inc
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
What does Galectin Therapeutics Inc do?
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
What does Galectin Therapeutics Inc's logo look like?
Complete history of Mr. Callicutt stock trades at Galectin Therapeutics Inc
Galectin Therapeutics Inc executives and stock owners
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Harold Shlevin,
Director -
Jack Callicutt,
Chief Financial Officer, Secretary -
Dr. Pol F. Boudes M.D., Ph.D.,
Chief Medical Officer -
Dr. Pol F. Boudes,
Chief Medical Officer -
Joel Lewis,
Pres, CEO & Director -
Kevin Freeman,
Independent Director -
Joel Lewis,
President, Chief Executive Officer, Director -
Richard Uihlein,
Independent Chairman of the Board -
Gilbert Amelio,
Independent Director -
Gilbert Omenn,
Independent Director -
Kary Eldred,
Independent Director -
Eliezer Zomer,
Executive Vice President - Manufacturing and Product Development -
Marc Rubin,
Independent Director -
James Czirr,
Director -
Richard Zordani,
Independent Director -
Elissa Schwartz,
Independent Director -
Pol Boudes,
Chief Medical Officer -
J. Rex Horton,
Executive Director - Regulatory Affairs and Quality Assurance -
Adam Allgood,
Executive Director of Clinical Development -
Beth Knowles,
Exec. Assistant & Officer Mang. -
Robert Tritt,
Gen. Counsel -
Jack W. Callicutt CPA, CPA,
CFO, Treasurer & Sec. -
Theodore Daniel Zucconi,
Director -
John F Mauldin,
Director -
Fund, L.P.10 X Capital Mana...,
-
Steven Prelack,
Director -
Arthur Greenberg,
Director -
Khurram Jamil,
Chief Medical Officer -
Benjamin Sr Carson,
-
Stephen Shulman,
Director -
Fund, L.P.10 X Capital Mana...,
-
Peter G Traber,
CEO and President -
Herman Paul Pressler,
Director -
Thomas Mcgauley,
Chief Financial Officer -
Rod D Martin,
Director -
Jerald K Rome,
Director -
Fund, L.P.Czirr James C10 X...,